Tag: Drug discontinuation

Acetaminophen overdose is a frequent cause of poisoning [1.3.7]. The primary antidote, N-acetylcysteine (Mucomyst), has specific protocols that address the critical question for clinicians: when should Mucomyst be discontinued for optimal patient safety and efficacy? [1.3.1, 1.3.4].

Up to 56% of patients receiving Lepirudin developed anti-lepirudin antibodies, a primary factor in its market withdrawal [1.3.4]. This article explains in-depth why was Lepirudin discontinued, exploring the clinical challenges and the shift towards safer anticoagulants for treating heparin-induced thrombocytopenia (HIT).

The voluntary withdrawal of Lumigan 0.03% bimatoprost ophthalmic solution in 2012 puzzled many patients, especially since the drug had proven effective in treating glaucoma. This decision by manufacturer Allergan was not due to a recall or safety issues but was instead a strategic move to focus exclusively on a more advanced, and better-tolerated, formulation. The development of the 0.01% solution offered the same efficacy with a lower incidence of a common side effect.

With over 25 million Americans affected by asthma, many were concerned to hear about changes to their medication [1.6.5]. The crucial question is, **why was QVAR taken off the market?** The answer is not a safety recall, but a strategic business decision by its manufacturer, Teva [1.3.1].

According to research, most finasteride side effects, such as sexual dysfunction and changes in libido, typically diminish and resolve once you stop taking the medication. However, a small, rare subset of individuals report persistent symptoms, a condition known as Post-Finasteride Syndrome (PFS).

First approved in 1959, the branded formulations of the weight-loss medication Tenuate were eventually discontinued in the U.S., while the generic version (diethylpropion) faced significant restrictions and changes in market availability. Understanding **why was Tenuate discontinued** requires examining the drug's safety profile and the evolution of the weight-management drug market.

While the brand name version of paromomycin, Humatin, has been discontinued in the U.S., the generic antibiotic itself remains available for treating certain parasitic infections [1.2.5, 1.4.2]. This distinction is central to answering the query: 'Why is paromomycin discontinued?'.

In late 2024, the manufacturer AstraZeneca formally notified the U.S. Food and Drug Administration (FDA) of its decision to discontinue the type 2 diabetes medication Bydureon BCise. This followed the earlier removal of the original Bydureon formulation in 2021. The primary driver for taking BYDUREON off the market was competitive pressure and declining sales, rather than safety or recall issues.

High blood pressure is a common condition that, if untreated, can damage the brain, heart, and kidneys [1.7.7]. For years, eprosartan helped manage this, so many patients are now asking: **why was eprosartan discontinued?** The answer is clearer than you might think.

Over 8,000 patients received tacrine in clinical trials before its 1993 FDA approval. What is Cognex known for? Primarily, it was the brand name for tacrine, the very first medication used to treat mild to moderate dementia of the Alzheimer's type. Despite being a pioneer in Alzheimer's treatment, its history is marked by significant side effects, which led to its discontinuation.